Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation

Bone Marrow Transplantation volume 36, pages 977–983 (2005)Cite this article

Summary:

We retrospectively analysed the significance of FLT3 mutations in patients with acute myeloid leukemia (AML) having a normal karyotype, who were treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation (auto-PBSCT). In all, 34 patients with normal karyotype AML in first complete remission receiving high-dose chemotherapy and auto-PBSCT were analysed based on the presence or absence of FLT3/ITDs and FLT3/D835. They were 16 males and 18 females and with a median age of 41.5 years. FLT3/ITDs were detected in eight of 34 patients (23.5 %), and FLT3 D835 mutations in two of 34 patients (5.9%). White blood cell count (P=0.0087), serum concentration of lactate dehydrogenase (P=0.005), and percentages of peripheral blood (P=0.0131) and bone marrow (BM) blasts (P=0.0312) were significantly higher in patients showing the FLT3 mutations. Overall survival (OS) and disease-free survival (DFS) were similar between patients with or without FLT3 mutations (5 year DFS, 67.5 vs 68.55%, P=0.819; 5 year OS, 64.81 vs 78.88%, P=0.4457, by the log-rank test). FLT3 mutations demonstrate no further prognostic impact in patients with normal karyotype AML in first CR treated with high-dose chemotherapy and auto-PBSCT. Myeloablative chemotherapy supported by auto-PBSCT may overcome any poor prognostic implications of FLT3 mutations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Mrozek K, Heinonen K, Bloomfield CD . Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 19–47.

    Article  CAS  PubMed  Google Scholar 

  2. Bloomfield CD, Lawrence D, Byrd JC et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173–4179.

    CAS  PubMed  Google Scholar 

  3. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  4. Slovak ML, Kopecky KJ, Cassileth PA et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083.

    CAS  PubMed  Google Scholar 

  5. Gondo H, Harada M, Miyamoto T et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1997; 20: 821–826.

    Article  CAS  PubMed  Google Scholar 

  6. Harada M, Akashi K, Hayashi S et al. Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. The Fukouka Bone Marrow Transplant Group. Int J Hematol 1997; 66: 297–301.

    Article  CAS  PubMed  Google Scholar 

  7. Turner AM, Lin NL, Issarachai S et al. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996; 88: 3383–3390.

    CAS  PubMed  Google Scholar 

  8. Lyman SD, Jacobsen SE . c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101–1134.

    CAS  PubMed  Google Scholar 

  9. Nakao M, Yokota S, Iwai T et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911–1918.

    CAS  PubMed  Google Scholar 

  10. Yokota S, Kiyoi H, Nakao M et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997; 11: 1605–1609.

    Article  CAS  PubMed  Google Scholar 

  11. Kiyoi H, Naoe T, Nakano Y et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074–3080.

    CAS  PubMed  Google Scholar 

  12. Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752–1759.

    Article  CAS  PubMed  Google Scholar 

  13. Whitman SP, Archer KJ, Feng L et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001; 61: 7233–7239.

    CAS  PubMed  Google Scholar 

  14. Frohling S, Schlenk RF, Breitruck J et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100: 4372–4380.

    Article  CAS  PubMed  Google Scholar 

  15. Thiede C, Steudel C, Mohr B et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326–4335.

    Article  CAS  PubMed  Google Scholar 

  16. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE . Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000; 14: 675–683.

    Article  CAS  PubMed  Google Scholar 

  17. Kiyoi H, Towatari M, Yokota S et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333–1337.

    Article  CAS  PubMed  Google Scholar 

  18. Yamamoto Y, Kiyoi H, Nakano Y et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97: 2434–2439.

    Article  CAS  PubMed  Google Scholar 

  19. Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–625.

    Article  CAS  PubMed  Google Scholar 

  20. Bennett JM, Catovsky D, Daniel MT et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991; 78: 325–329.

    Article  CAS  PubMed  Google Scholar 

  21. Makino S, Harada M, Akashi K et al. A simplified method for cryopreservation of peripheral blood stem cells at −80 degrees C without rate-controlled freezing. Bone Marrow Transplant 1991; 8: 239–244.

    CAS  PubMed  Google Scholar 

  22. Wheatley K . Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? – a statistician's view. Br J Haematol 2002; 118: 351–356.

    Article  PubMed  Google Scholar 

  23. Boissel N, Cayuela JM, Preudhomme C et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699–1704.

    Article  CAS  PubMed  Google Scholar 

  24. Schnittger S, Schoch C, Dugas M et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59–66.

    Article  CAS  PubMed  Google Scholar 

  25. Kainz B, Heintel D, Marculescu R et al. Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J 2002; 3: 283–289.

    Article  CAS  PubMed  Google Scholar 

  26. Beran M, Luthra R, Kantarjian H, Estey E . FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype. Leuk Res 2004; 28: 547–550.

    Article  CAS  PubMed  Google Scholar 

  27. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896–903.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

    G Yoshimoto, K Nagafuji, T Miyamoto & M Harada

  2. Department of Medical Information Science, Kyushu University Hospital, Fukuoka, Japan

    N Kinukawa

  3. Department of Hematology, Hamanomachi General Hospital, Fukuoka, Japan

    K Takase, T Eto & K Kato

  4. Department of Hematology, Harasanshin Hospital, Fukuoka, Japan

    S Hayashi & T Kamimura

  5. Department of Hematology, Kitakyushu Municipal Hospital, Kitakyushu, Japan

    Y Ohno

  6. Department of Hematology, Toranomon Hospital, Tokyo, Japan

    S Taniguchi

Authors
  1. G Yoshimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Nagafuji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Kinukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Takase
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Eto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Kamimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Y Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Taniguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Nagafuji.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshimoto, G., Nagafuji, K., Miyamoto, T. et al. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 36, 977–983 (2005). https://doi.org/10.1038/sj.bmt.1705169

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705169

Keywords

This article is cited by

Search

Advanced search

Quick links